Synthesis and cell growth inhibitory properties of substituted (E)-1-phenylbut-1-en-3-ones

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 24, 1997, Pages 3091-3094

  Ducki, Sylvie ^a,b   Hadfield, John A ^b   Hepworth, Lucy A ^a   Lawrence, Nicholas J ^a   Ching Ying, Liu ^a   McGown, Alan T ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 HYDROXYPHENYL 1 BUTEN 3 ONE; 1 (PENTAFLUOROPHENYL) 1 BUTEN 3 ONE; 1 PHENYL 1 BUTEN 3 ONE DERIVATIVE; CYTOTOXIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL LINE; CHIRALITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; REACTION ANALYSIS; STEREOCHEMISTRY;

EID: 0031455796     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)10147-0     Document Type: Article

References (17)

1. 'Human medicinal agents from plants', eds. Kinghorn, A. D.; Balandrin, M. F.; ACS symposium series, 534, American Chemical Society, Washington, DC, 1993.
2. Qian, B. Clinical Effects of Anticancer Chinese Medicine, Shanghai Translation Publishing House, 1987.
3. Ducki, S.; Hadfield, J. A.; Lawrence, N. J.; Liu, C.-Y.; McGown, A. T.; Zhang, X. G. Planta Medica, 1996, 62, 185-186.
4. Edmondson, J. M.; Armstrong, L. S.; Martinez, A. O. J. Tissue Culture Methods, 1988, 11, 15-17.
5. Higuchi, R., Donnelly, D. M. X. Phytochemistry, 1977, 16, 1587-1590.
6. Abe, N.; Fujisaki, F.; Sumoto, K.; Miyano, S. Chem. Pharm. Bull., 1991, 39, 1167-1170; Dhawan, D.; Grover, S. K. Synth. Commun., 1992, 22, 2405-2409.
7. Abe, N.; Fujisaki, F.; Sumoto, K.; Miyano, S. Chem. Pharm. Bull., 1991, 39, 1167-1170; Dhawan, D.; Grover, S. K. Synth. Commun., 1992, 22, 2405-2409.
8. Method A: A mixture of the substituted benzaldehyde 5 (10 mmol), acetone (20 ml) and 10% aqueous sodium hydroxide (20 ml) was left to stand at ambient temperature overnight. Water was added and the mixture was extracted with chloroform, dried over anhydrous magnesium sulfate, filtered, evaporated in vacuo and recrystallised to give the trans-phenylbutenone 4.
9. Shibata, I.; Nishio, M.; Baba, A.; Matsuda, H. Chem. Lett., 1993, 1219-1222.
10. Method B: Diketene (2 mmol) 6 and bis-(tri-n-butyltin)oxide (2 mmol) were stirred in dry THF (2 ml) under a nitrogen atmosphere at 0 °C for 15 mins. The substituted benzaldehyde 5 (2 mmol) in dry THF (2 ml) and 1,3-dimethyl-3,4,5,6-tetrahydro-2(1)-pyrimidinone (2 mmol) were added and the mixture was stirred for a further 4 hours at 40 °C. Aqueous methanol was added and the mixture was evaporated. The residue was purified by chromatography (silica) and recrystallised from hexane to give the trans-phenylbutenone 4.
11. All compounds were fully characterised and gave the expected spectral and analytical data; Microanalysis confirmed their chemical purity (values for C and H within 0.3%).
12. 'Fluorine in Medicine in the 21st Century', Conference papers, UMIST, UK, April 18-21, 1994.
13. Beekman, A. C.; Woerdenbag, H. J.; van Uden, W.; Pras, N.; Konings, A. W. T.; Wikström, H. V.; and Schmidt, T. J. J. Nat. Prod., 1997, 60, 252-257.
14. Elias, G.; Roa, M. N. A. Eur. J. Med. Chem., 1988, 23, 379-380.
15. Jagetia, G. C., Jacob, P. S., Rao, M. N. A. Mutation Research, 1994, 306, 71-80.
16. Elias, G.; Roa, M. N. A. Ind. J. Pharm. Sci., 1988, 50, 339-341.
17. Saldanha, L. A.; Elias, G.; Rao, M. N. A. Arzneim.-Forsch./Drug Res., 1990, 40, 89-91.